Daily Chart

Send a Tweet

$NVS
#Novartis Ag-adr
NVS
Novartis Ag-adr
Look for:
NVS
Pre-Market Movers: $NVO,$FCL,$PCZ,$GSK,$ERTS,$HBC,$DDR,$DB,$GFA,$NVS...more
NVS
Novartis $NVS in-licenses a mid-to-late-stage experimental hepatitis C drug from a private Swiss co. Gains exclusive WW rights,except Japan.
NVS
Monday February 8 2010 MACD Sell Signal $ALXN $BAP $GILD $MCD $ROST $NVS $PETD $PII $LKFN $NTY #economics
NVS
@drpdtapp yes $NVS have Afinitor and $GSK have pazopanib. There are 6 approved in renal cc now
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. $RHHBY $NVS (@mhuckman)
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. Crew tweaking lights now. $RHHBY $NVS
NVS
Allergan’s Looking Real Pretty Right Now http://cnbc.com/id/35238576 $ABT $ACL $AGN $NVS #StockPicks #StockMarket
NVS
RT@MhuckmanRoche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHH
NVS
Roche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHHBY $NVS
NVS
Pfizer Earnings By the Numbers http://cnbc.com/id/35196988 $AMGN $BIIB $GENZ $GILD $MRK $NVS $PFE $WAT #StockMarket
NVS
$NVS $CSBTF Hypertension Market Will Be Constrained Through 2018 by Pipeline Containing Few Novel Emerging Therapies http://bit.ly/c3boXR
NVS
Is Genentech/Roche turning a blind eye to a marketing/PR opportunity for Lucentis/Avastin? Vote in the poll. http://bit.ly/9VSjxq $NVS
NVS
RT @adamfeuerstein: @mhuckman: Kaiser "real-world" study:Avastin = Lucentis for AMD. $NVS $RHHBY Genentech: Only L proven safe,eff
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
RT @mhuckman: Kaiser "real-world" study:Avastin works as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.




Novartis Ag-adr - NVS Insiders

No Insiders

We have no insiders for Novartis Ag-adr right now.

Know someone who is an insider on Novartis Ag-adr?
Let us know.

Novartis Ag-adr - NVS information

...
135,696 Employees
Last Reported Date: 01/29/14
Founded in 1895
Last $84.67 USD
Change Today +0.26 / 0.31%
Volume 969.6K
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVS) Snapshot

Open
$84.35
Previous Close
$84.41
Day High
$84.89
Day Low
$84.13
52 Week High
03/31/14 - $85.23
52 Week Low
06/24/13 - $67.67
Market Cap
229.1B
Average Volume 10 Days
1.7M
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
$2.76
Dividend Yield
3.26%
Request Investor Kit
NVS:US Advanced Stock Chart

novartis ag-adr (NVS) Related Bloomberg News

Fed Taper Question Keeps U.S. Corporate Bond Sales Below Average
Novartis Jury Awards $10.45 Million for Drug, Lawyer Says
Novartis’s Alcon Wins Bid to Block Apotex’s Generic Patanol
Teva’s Patents Infringed, U.S. Judge Rules
Risk Panel, Lloyds Capital, Pharma Overtime: Compliance

novartis ag-adr (NVS) Related News

The Law of Gravity Isn't Working for This Off-Patent Drug
Once a Notorious Short Seller, Martin Shkreli Now Sees a Future in Biotech
Europe Moves to Make Drug Trial Data More Transparent
Surprise! Generic-Drug Prices Spike
[addPosition2]

novartis ag-adr (NVS) Key Developments

Novartis Opens Third Clinical Testing Centre in Philippines

Novartis is opening a third clinical testing centre in the Philippines, having signed a memorandum of understanding with the Philippine Heart Centre (PHC) to establish a Center for Excellence for Clinical Trials (CETC), as reported by Business Mirror. Under the deal, Novartis will be able to make use of the PHC as a priority site for clinical trials in the Philippines, and will provide researcher training to the hospital's clinical team. The focus of research activities will be good clinical practice, pharmacovigilance, biotechnology workshops, and capacity building in relation to clinical trial protocols review.

Sandoz Launches Asthma and COPD Inhaler in Norway

Sandoz has launched AirFluSal Forspiro, a new inhaler for patients with asthma and/or chronic obstructive pulmonary disease, or COPD, in Norway. In Norway, Sandoz is launching the 50/250 µg and 50/500 µg dosage forms for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD. The device features an innovative, patient-friendly design, including multiple feedback mechanisms: visual control features which help reassure the patient about dosing; simple lever arm to load the dose; and clear and accurate dose counter.

Novartis Announces Closing of PARADIGM-HF Trial for Chronic Heart Failure

Novartis  announced that  the Data Monitoring Committee  (DMC) recommended early closure of the PARADIGM- HF study, indicating  patients with chronic  heart failure with  reduced ejection fraction (HF- REF)  who received LCZ696 lived longer  without being hospitalized for heart  failure  than  those  who  received  standard care with ACE-inhibitor enalapril.  Based on the compelling efficacy and primary endpoint having been met, the trial  will now close early. This follows two previous interim analyses that showed the  safety profile of LCZ696 was acceptable. The  results of PARADIGM- HF will be submitted  to a major medical conference for  presentation  and  Novartis  will  now  initiate  discussions with global health  authorities regarding approval for marketing. LCZ696,  a twice a day pill for heart failure, is a medicine that  acts  in  multiple  ways  on  the  neurohormonal  systems of the heart, blocking  receptors  exerting  harmful  effects  while simultaneously promoting protective  mechanisms.  Known  as  an  ARNI  (Angiotensin  Receptor  Neprilysin Inhibitor)  LCZ696  is  thought  to  reduce  the  strain  on  the failing heart,  promoting the ability of the heart muscle to recover.  PARADIGM-HF  is a randomized,  double-blind, Phase III  outcome study evaluating  the  efficacy and safety profile  of LCZ696 versus enalapril  (a widely used ACE  inhibitor)  in 8,436 patients with heart failure with reduced ejection fraction  (HF-REF). The primary outcome is a composite of time to first occurrence  of  either cardiovascular death or heart failure hospitalization, and the trial  is also designed to be able to detect a significant difference in cardiovascular  death. The study  was initiated  in December  2009 and currently  is the largest clinical trial in heart failure ever undertaken.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $84.67 USD +0.26

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $98.96 USD +0.21
Nestle SA SFr.67.25 CHF +0.55
Pfizer Inc $30.25 USD +0.16
Roche Holding AG SFr.254.90 CHF +0.70
Procter & Gamble Co/The $81.76 USD +0.11
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 22.9x
Price/Sales 3.5x
Price/Book 2.8x
Price/Cash Flow 24.9x
TEV/Sales 3.4x
 | 

Post a JobJobs

  • Consultant - Implementation Services
    San Francisco, CA | Smartrecruiters
    Posted: Apr 09
  • Senior Business & Technology Specialist
    Washington, DC | DC Bar
    Posted: Apr 09
  • Associate Director, Business & Technology
    Washington, DC | DC Bar
    Posted: Apr 09
  • VP of Software Development
    Carlinville, IL | Karmak
    Posted: Mar 25
Simply Hired

Sponsored Financial Commentaries

Sponsored Links

Novartis Ag-adr - NVS news

3 Mega-Cap Dividend Stock Ideas

Quote:
Read article

US doctor pleads guilty in securities case

Keywords: US doctor pleads guilty in securities case, nvs, pe-and-hedgefunds
Quote:
Read article

Awaiting Novartis acquisition, biotech firm Proteon raises $15.2M

Quote:
Read article

Will Investors Regret Leaving The US?

Keywords: ETFs,Investing,Markets,Stocks,Business,Exchange-traded fund,Forbes,IShares,Research and Analysis,Shares outstanding,Trade
Quote:
Read article

LEAD 1-Nestlé porté par la croissance dans les pays émergents

Quote:
Read article

UPDATE 1-Vectura extends VR315 deal with Sandoz to new areas

Keywords: United States, Will Waterman
Quote:
Read article

Momenta's earnings rise on market grab from Sanofi

Quote:
Read article

[$$] Novartis' MS Pill Questioned by U.K. Regulator

Quote:
Read article

9 Swiss Stocks That May Be a Haven

Quote:
Read article

Advisers steer clients to safer havens in stormy market

Keywords: Greece, Italy, Switzerland, RichardSatran, S&P 500
Quote:
Read article

Vanda Pharmaceuticals reports loss

Quote:
Read article

Swiss stocks - Factors to watch on Aug 5

Quote:
Read article

FDA: Generic biotech drugs require paradigm shift

Keywords: Israel, United States, Michele Gershberg, Phil Berlowitz
Quote:
Read article

UPDATE 2-Vectura gets new U.S. partner for copy of lung drug

Keywords: United States, Andrew Callus
Quote:
Read article

UPDATE 1-Vectura strikes new U.S. deal for lung drug VR315

Keywords: United States
Quote:
Read article

UPDATE 1-Finnish drug maker Orion Q2 meets forecast

Keywords: Switzerland, Jane Merriman
Quote:
Read article

Vanda aims for Argentina

Quote:
Read article

Buyout firms to bid for GSK drugs portfolio-sources

Keywords: Britain, Jane Merriman
Quote:
Read article

PDL posts bigger 2Q profit on lower legal costs

Keywords: PDL posts bigger 2Q profit on lower legal costs, nvs,pdli, earnings
Quote:
Read article

Flu "super antibody" may bring universal shot closer

Quote:
Read article
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.